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1. Introduction
In an increasingly complex scientific and technological environment, firms do not conduct 
their innovative activities in isolation, but are embedded in their surroundings. Literature 
argues that the locus of innovation is no longer the individual actor, but the entire network 
(Powell and Brantley 1992; Powell and Grodal 2005; Powell, Koput, and Smith-Doerr 1996). 
Moreover, a stream of literature suggests that a firm’s position within a research network 
influences its innovative output, particularly in industries in which the knowledge base is 
rapidly developing, complex and widely dispersed (Owen-Smith et al. 2002; Powell et al. 
1999). The reason is that in these industries, no organization can simultaneously be up to 
date with the progress in all knowledge areas necessary for successful innovative activi-
ties (Nooteboom 1999, 2009). Hence, collaboration through networks is a means to pool, 
exchange and develop new knowledge. Under these conditions, the structure of the entire 
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network as well as the actors’ position within it determine their access to the relevant knowl-
edge sources. Therefore, the network will affect actors’ innovative activities and performance 
(Kogut, Shan, and Walker 1992). In the case of biotechnology and pharmaceuticals, the 
development of new products strongly relies upon novel ideas, particularly those generated 
through medical and biological scientific research. However, at the same time, the capa-
bilities of the firm in acting in this complex network and fast-paced environment must be 
investigated as well. Our paper contributes to the literature, by untangling the influence of 
the firm’s collaborative relations with different partner types and their network position, 
within the specific area of biotechnology and pharmaceutical industry.
In their literature review, Phelps, Heidl, and Wadhwa (2012) point out that research 
addressing the relationship between companies’ collaborative relations and their position 
within networks has led to conflicting results concerning the influence of these factors on 
innovative performance. The authors conclude that the number of collaboration partners 
per se does not sufficiently account for the diversity of collaborative relations, knowledge 
generation and exchange. In this paper, we are interested in networks in the context of the 
firm, and its innovative performance. Networks may be useful because the recombination of 
existing knowledge is as an important source of novelty and innovation (Nelson and Winter 
1982; Schumpeter 1939). Hence, conceptually, companies can use collaboration in networks 
as a complementary activity to their internal capabilities for knowledge and innovation.
The pharmaceutical and biotechnology industry is a particularly interesting and impor-
tant context to try to further untangle the relationships between partners for scientific 
publications, networks and innovative performance of the firm. Recent research has demon-
strated the increasing importance of networks and collaboration partners in promoting new 
products in this industry (Rafols et al. 2014). The pharmaceutical industry is characterized 
by tremendous growth in R&D and in collaboration for development and marketing among 
different types of actors (Powell et al. 2005; Roijakkers and Hagedoorn 2006). Within the 
pharmaceutical sector, networks are created by interactions between heterogeneous actors, 
who are linked through a web of different types of relations involving knowledge, markets, 
regulations and so forth (McKelvey, Orsenigo, et al. 2004). Thus, research for pharmaceu-
tical product innovations is increasingly conducted in collaboration with a broad range of 
different partners, and innovations rely upon numerous actors, who are involved at different 
stages from drug discovery to drug testing and approval.
Within this industry, this paper focuses upon knowledge and innovation for one specific 
disease area, namely cancer. Few—if any—existing studies have examined cancer pharma-
ceutical research in terms of the global nature of networks across multiple types of actors 
and the impact on product innovation. Cancer research is a vital area for both public and 
private investment into health care, and represents a treatment area with an expanding 
market for pharmaceuticals. Cancer is one of the leading causes of death worldwide, with 
approximately 8.2 million individuals succumbing to cancer every year and more than 14 
million new cases diagnosed annually. According to the International Agency for Research 
on Cancer (International Agency for Research on Cancer 2014) both numbers are expected 
to rise considerably in the course of the next two decades. Hence, cancer research is an 
important area to study, given societal health concerns. Moreover, studying the case of global 
cancer research provides more insights than restricting the study to one country. With global 
data we can more thoroughly examine the dynamic complexity of how successful product 
innovations are based on, and can be traced back to, cancer research.
IndusTRy and InnovaTIon  385
The objective of this paper is to explain successful product innovation success at the firm 
level, based upon collaboration with different partner types and firms’ position in the global 
co-publication network for cancer research. Note that, in contrast to previous research, the 
paper uses a more specific proxy for product innovation in cancer, namely new molecular 
entities (NMEs) approved by the Food and Drug Administration (FDA), i.e. drugs that 
have not been marketed before.
Section 2 provides a literature overview, relative to the objective of this paper, and gener-
ates hypotheses. Section 3 explains the empirical strategy, data and research design. Section 
4 describes the results of the econometrics and network analysis, relative to the hypotheses, 
while Section 5 provides conclusions and implications for later research.
2. Literature
2.1 Relating knowledge, collaboration and innovation
Studying the effects of the firm’s networks on innovative output is, in the context of this 
paper, related to a specific theory of the firm. Literature on the theory of the firm rec-
ognizes that the generation of new, and the deployment of existing, knowledge is one of 
the principal sources of companies’ competitive advantage (Grant 1996; Teece 2000). The 
underlying reasoning is that companies’ knowledge bases translate into innovation activities 
that in turn allow for the development of new products, processes or services as well as the 
improvement of existing ones. Hence, the continuous generation of knowledge is one of 
the companies’ most important objectives (Nonaka, Toyama, and Nagata 2000). Knowledge 
generation itself can be characterized by a largely cumulative step-by-step process in which 
new knowledge builds upon an existing foundation (Scotchmer 1991). However, the mere 
existence of knowledge does not imply that it is accessible and can be used by third par-
ties (Mokyr 2002). Consequently, companies and other organizations need capabilities to 
effectively and efficiently search for, access, transfer, absorb and apply existing knowledge 
(Kogut and Zander 1992).
Therefore, the firm’s capabilities to collaborate through networks matter because the 
recombination of existing knowledge is as an important source of novelty and innovation 
(Nelson and Winter 1982; Schumpeter 1939). Companies can use collaboration, in addi-
tion to their own investments, to further develop their knowledge base. Consistent with 
this, numerous studies indicate a positive relationship between R&D collaboration and 
companies’ innovative performance in terms of patenting across countries and industries 
(Branstetter and Sakakibara 2002; Brouwer and Kleinknecht 1999; Czarnitzki, Ebersberger, 
and Fier 2007; Sampson 2007). In line with these results, Becker and Dietz (2004) find that 
R&D collaboration and the number of partners involved in the collaboration increase the 
probability of developing new products.
Literature regarding other industries suggests that collaboration with a diverse set of 
national and international partners, including suppliers, customers, competitors as well as 
universities and public research organizations, contributes to companies innovative per-
formance (Duysters and Lokshin 2011; de Leeuw, Lokshin, and Duysters 2014). In the 
case of pharmaceuticals and medical care, discovering and implementing innovations 
requires a complex institutional arrangement, from research financing and collaborative 
development between partners to set up agreements on how to run clinical testing and 
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apply for market approval (Windrum and García-Goñi 2008). Innovation, regulation and 
sales activities are complex in pharmaceuticals given the extensive involvement of public 
and private stakeholders (McMillan, Narin, and Deeds 2000; Murray 2002). These public 
and private stakeholders can range from pharmaceutical and biotechnology companies to 
universities and research institutes, insurance providers, medical care providers as well as 
NGOs or foundations which are engaged in cancer prevention, diagnosis and treatment, 
or the generation of new medical knowledge.
Therefore, the first hypothesis relates to having partners:
Hypothesis 1: The total number of collaboration partners in scientific publications is positively 
related to the development of new pharmaceuticals in the area of cancer.
However, the mere number of collaboration partners does not fully account for the quality 
and diversity of knowledge a company can access through its collaboration activities in 
order to support its innovative performance (Phelps 2010; Phelps, Heidl, and Wadhwa 
2012). Therefore, one must turn to the specific types of collaboration and partners which 
characterize the intense collaboration activities the industry developed as a response to the 
rapidly developing, complex and widely dispersed knowledge base (Arora and Gambardella 
1994; McKelvey 1996; Orsenigo, Pammolli, and Riccaboni 2001).
Biotechnology companies are an important type of partner. One reason why pharma-
ceutical and biotechnology firms collaborate is to make use of the complementarity of 
companies’ key resources, knowledge bases and competencies as well as the opportunity to 
incorporate entrants’ knowledge and competencies into incumbents’ value chains (Arora 
and Gambardella 1994; Gambardella 1995; McKelvey 1996; Powell and Brantley 1992; 
Rothaermel 2000). Put differently, incumbent pharmaceutical firms have been interested 
in collaborating with biotechnology companies to gain access to, and experience with, new 
techniques that have created opportunities for the development of new pharmaceuticals 
(Malerba and Orsenigo 1996; McKelvey, Orsenigo, et al. 2004). In turn, collaboration enables 
biotechnology companies to access competencies and resources for the clinical development, 
approval and marketing of new drugs (Malerba and Orsenigo 1996; McKelvey, Rickne, et al. 
2004). Empirical evidence on this phenomenon suggests that R&D collaboration between 
incumbents and biotechnology companies as providers of new technologies is positively 
related to the number of new product developments by the incumbents (Rothaermel 2001). 
However, in subsequent research, several authors have stressed that the R&D alliances 
between biotechnology and pharmaceutical companies have not lead to an increasing rate 
of drug discovery (Hopkins et al. 2007; Pisano 2006).
Thus, existing literature provides contradictory results, based on different empirical 
observations, of the effects of collaboration between biotechnology and pharmaceutical 
companies and the effects on innovative performance. We therefore propose a positive and 
a negative hypothesis.
Hypothesis 2a: The number of biotechnology collaboration partners in scientific publications 
is positively related to the development of new pharmaceuticals in the area of cancer.
Hypothesis 2b: The number of biotechnology collaboration partners in scientific publications 
is negatively related to the development of new pharmaceuticals in the area of cancer.
Universities and public research institutes are another important partner type in order 
to access more basic knowledge. Extensive research based on observations from differ-
ent industries has identified advantages and disadvantages for the firm from this type of 
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collaboration. Cassiman and Veugelers (2002, 1,179) find “firms that find the publicly avail-
able pool of knowledge more important for their innovation process [to be] more likely 
to benefit from cooperative agreements with other research institutes.” The positive effect 
of R&D collaboration on innovative performance has also been demonstrated in this con-
text (Shan, Walker, and Kogut 1994). Collaboration between pharmaceutical firms and 
academic institutions is essential for successful innovative activities because the industry’s 
R&D process is directly based on scientific knowledge (Cockburn and Henderson 1998).1
Empirical evidence suggests that collaboration between pharmaceutical companies and 
academic institutions through co-authorship of scientific papers, increases the number of 
patents granted in at least two of the three most important markets, i.e. the United States, 
Western Europe and Japan (Cockburn and Henderson 1998). Moreover, biotechnology 
companies collaborating with universities simultaneously have lower R&D expenditures 
and higher innovative outputs in terms of patents, marketed products and products under 
development (George, Zahra, and Robley Wood 2002).2
The reasons why collaboration between firms and academic institutions in scientific 
publications may positively affect subsequent innovative performance are manifold (Faems, 
Van Looy, and Debackere 2005; Soh and Subramanian 2014). One has to do with access to 
complementary assets necessary to innovate, especially in a science-based industry; another 
is to stimulate the transfer of tacit as well as codified knowledge through collaboration; and 
a final is to spread the risks of R&D among different partners.
Therefore, this part of the literature suggests a positive impact on innovation of collab-
oration between companies and academic institutions.
Hypothesis 3: The number of academic collaboration partners in scientific publications is 
positively related to the development of new pharmaceuticals in the disease area of cancer.
2.2 Networks and innovative performance
Moving beyond direct interactions with different types of partners, indirect ties and the 
position within the network may also influence the firm’s product innovation. A key con-
ceptualization underlying the literature on knowledge and innovation networks is that 
collaboration networks do not only provide access to the knowledge and experience of direct 
partners, but also to the knowledge and expertise of their partners’ collaborators (Gulati 
and Gargiulo 1999). Beckman and Haunschild (2002) provide evidence that these indirect 
linkages supply companies with valuable and diverse information. Ahuja (2000) demon-
strates the relevance of indirect linkages for firms’ innovative activities, i.e. their number 
of patents. In line with our argument presented in Section 2.1, we propose that companies 
may benefit from indirect knowledge inflows from different types of organizations that they 
are connected with through their direct collaboration partners. Our hypotheses for indirect 
relations follow the above arguments for direct collaboration defined by type of partner:
Hypothesis 4: The total number of indirect collaboration partners in scientific publications 
is positively related to the development of new pharmaceuticals in the disease area of cancer.
1small biotechnology companies are also dependent upon public science Feldman (2000).
2However, companies’ financial performance is ultimately not superior to their counterparts without university linkages 
(George, Zahra, and robley Wood 2002).
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Hypothesis 5a: The number of indirect biotechnology collaboration partners in scientific pub-
lications is positively related to the development of new pharmaceuticals in the disease area 
of cancer.
Hypothesis 5b: The number of indirect biotechnology collaboration partners in scientific pub-
lications is negatively related to the development of new pharmaceuticals in the disease area 
of cancer.
Hypotheses 6: The number of indirect academic collaboration partners in scientific publications 
is positively related to the development of new pharmaceuticals in the area of cancer
Indeed, network analysis is needed because the network may be the locus of innovation, 
due to opportunities to pool, exchange and develop new knowledge (Powell and Brantley 
1992; Powell and Grodal 2005; Powell, Koput, and Smith-Doerr 1996) This notion relies 
on the assumption that knowledge is exchanged among the members of a collaboration 
network through formal and informal channels including collaborative work, technical 
and scientific advice as well as other forms of information exchange (Schrader 1991). These 
knowledge flows occur through the exchange of one’s own and acquired knowledge among 
collaboration partners acting as both receiver and transmitter of knowledge (Gulati and 
Gargiulo 1999; Rogers and Kincaid 1981). Consequently, centrally located companies may 
have the largest opportunities to get access to more knowledge of greater fidelity (Hansen 
2002; Monteiro, Arvidsson, and Birkinshaw 2008; Reagans and McEvily 2003).
Eigenvector centrality is a particularly useful concept in terms of potential knowledge 
exchange since it does not only take the connectivity of an individual company into account, 
but also the connectivity of its direct collaboration partners (Bonacich 1972, 1987, 2007). 
Companies with high eigenvector centrality scores should benefit from their position in 
the network since they get a higher amount and faster access to knowledge that is valuable 
for their own R&D activities (Salman and Saives 2005).
Hagedoorn and Duysters (2002) find that eigenvector centrality based on technology 
alliances does not contribute to computer companies’ technological performance in terms 
of patents. Using an extensive data-set on human biotechnology firms, Powell et al. (1999) 
find evidence that central network positions in terms of eigenvector centrality are positively 
related to a broad variety of performance measures, such as sales, employment growth, the 
number of patents and internally funded R&D expenditures. In the context of US-based 
life science companies, Whittington, Owen-Smith, and Powell (2009) show that eigenvector 
centrality contributes to patent applications. Therefore:
Hypotheses 7: Companies’ eigenvector centrality in a network of scientific publications is 
positively related to the development of new pharmaceuticals in the area of cancer.
Finally, another network measure is betweenness centrality, which incorporates the idea 
that interactions between non-neighboring actors within a network depend on other actors 
lying on a path between the two. Companies in this position may be seen as knowledge bro-
kers which are participating actively in knowledge exchange within the network. By doing 
so, these companies get access to a diverse set of knowledge and thus support companies’ 
innovative activities (Freeman 1979; Salman and Saives 2005).
In line with the latter arguments, Salman and Saives (2005) find a positive relationship 
between biotechnology companies’ betweenness centrality in a network of strategic partner-
ships and their innovative performance. Regarding the biotechnology industry near Boston, 
Owen-Smith and Powell (2004) find that the relation between betweenness centrality and 
innovative activities can change as the network develops over time. More precisely, the 
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authors find a negative relation between central network positions and successful patent 
applications in the early years of the network. It is important to note that as the network 
becomes more mature, centrality is positively associated with innovation. The changing 
importance of centrality is connected to the increasing importance of for-profit organ-
izations, such as biotechnology companies and venture capitalists, in the local network 
(Owen-Smith and Powell 2004). Therefore:
Hypotheses 8: Companies’ betweenness centrality in a network of scientific publications is 
positively related to the development of new pharmaceuticals in the disease area of cancer.
3. Data, empirical strategy and research design
3.1 Data
Our empirical analysis is based on a unique database for pharmaceutical cancer research, 
compiled from different sources. More precisely, we employ data on scientific publications, 
new drug approvals and the pharmaceutical companies found to be publishing in the field 
of cancer.
Data on publications provide a reasonably good, but partial indicator of collaborative 
knowledge production (Hoekman, Frenken, and van Oort 2009; Tijssen 2009). Here, it is 
used to build collaboration networks and to identify the different types of actors. To collect 
data on scientific co-publication, the BioPharmInsight database was used to compile a list 
of 30 medical indications in the therapeutic area of cancer.3 Each indication describes a 
medical condition or disease that allows for the development of a pharmaceutical therapy.
We used these medical indications in order to conduct a keyword search in the Web 
of Science databases (WoS), gathering data on scientific publications. In our data-set, we 
include all publications that contain at least one of the respective medical indications in their 
title. Further, we restrict the publication data to areas related to pharmaceutical research, i.e. 
those which have been assigned to the WoS categories “Biochemistry & Molecular Biology,” 
“Biotechnology & Applied Microbiology,” “Chemistry, Applied,” “Chemistry, Medicinal,” 
“Medicine, Research & Experimental,” “Pharmacology & Pharmacy” or “Toxicology.”4 
Moreover, we exclude all publications that are not classified as journal articles to ensure 
that our data fulfill minimal criteria in quality and originality and also provides detailed 
information concerning the content and the origin of the publication.
To construct collaboration networks based on co-publications, we distinguish two 
sub-periods, 1998–2002 and 2004–2008. To create periods of equal length and to distinguish 
clearly between the two sub-periods, we do not use articles published in 2003. In total, the 
sample consists of 17,259 journal articles for which author affiliations have been reported 
in the WoS database. These affiliations are used to assign publications to the organizations 
from which they originated. More specifically, given the aims of this paper, we distinguish 
between academic institutions, i.e. universities, public research institutes and biotechnology 
companies as collaboration partners for the firms in our sample based on reported author 
affiliations. For companies, we checked manually whether their main line of business could 
3http://www.biopharminsight.com/index.html. a list of the respective medical indications can be found in table a1 in the 
appendix 1.
4a description of the categories can be found at http://ip-science.thomsonreuters.com/cgi-bin/jrnlst/jlsubcatg.cgi?PC=d.
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be described as traditional pharmaceuticals, biotechnology according to the biotechnology 
definition of the OECD (Organisation for Economic Co-operation and Development 2005) 
or whether the companies had another main line of business such as the production of 
chemicals, food or diagnostic devices.
Data on new molecular entities approved by the US Food and Drug Administration 
(FDA) are used as our proxy for successful product innovation. We obtained data on new 
pharmaceuticals in the disease area of cancer from the Drugs@FDA database.5 The database 
contains information on the trade name of new drugs, their generic names, the components 
providing pharmacological activity, the approval date and a classification of the newness 
of a drug formulation.
We match the medical indications with data on new molecular entities based on their 
pharmacological active ingredients. To match these elements, we follow Cerda (2007) in 
consulting the nineteenth edition of the Drug Information Handbook published by Lexi-
Comp and the American Pharmaceutical Association (Lacy et al. 2010). The handbook 
provides a list of the drugs’ active ingredients, the medical indications the respective drug is 
used for and further information, such as adverse effects. Note that we consider only medical 
conditions that are listed on the FDA approved label. Hence, unlabeled and investigational 
uses are not considered.
Assigning publications and NMEs to the appropriate organization based on reported 
affiliations and applicants’ names required several steps of standardization since the differ-
ent types of raw data do not contain standardized organization names. We used publicly 
available information such as the organizations’ websites, company reports, SEC filings as 
well as business information provided by Bloomberg as basis for the manual standardization 
of organization names. We account for changes in organizational boundaries, e.g. due to 
mergers and acquisitions, by assigning each institution to its highest order independent 
entity by 2008. We apply this strategy in order to take all collaboration and innovation 
activities into account, irrespective of the report of subsidiaries as author affiliations or as 
drug applicants. Specifically, all subsidiaries are assigned to the parent company if the latter 
holds more than 50 per cent of the shares. Following this rule, we also assign government 
agencies and laboratories to the responsible institution as well as research institutes to the 
corresponding umbrella organizations.6 As there is no clear distinction between university 
hospitals and medical departments, we therefore consider university hospitals as part of 
the university with which they are affiliated.7
We consulted different databases to obtain financial information for the 325 companies 
that published at least one scientific article from 1998 to 2002. The databases used did 
provide similar types of data about firms, but with different areas of coverage. The 
Amadeus database was used to obtain information on companies based in Europe. We 
supplement the data for firms headquartered outside Europe with data obtained from 
their financial reports provided by Company.info and the US Securities and Exchange 
Commission (SEC). Financial data are converted to US dollars using the exchange rate 
at the end of the respective year.
5http://www.fda.gov/drugs/Informationondrugs/ucm135821.htm.
6this implies that different research institutes of the Max Planck society are summarized as Max Planck society.
7this implies that articles reporting, e.g. dana–Farber Cancer Institute as affiliation, are assigned to Harvard university. the 
same applies to articles reporting Harvard Medical school as affiliation.
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The ReCap database is consulted to obtain data on firms’ strategic R&D alliances.8 The 
ReCap database contains information on alliances in the bio-pharmaceutical industry col-
lected from various sources including press releases, SEC filings and company presentations. 
We restrict the ReCap data to alliances that focus on research and development activities 
in the field of cancer research.
3.2 Empirical strategy to analyze collaboration and product innovation
Our empirical strategy builds upon tools from social network research to analyze the rela-
tionship between firms’ collaborative relations and their innovative success in pharma-
ceutical cancer research. Relations among organizations in networks are represented by 
co-publication links. The underlying assumption is that co-authors of a scientific publica-
tion have collaborated in its production. This assumes that they have engaged in the joint 
generation of new knowledge and in certain types of knowledge transfer that may facilitate 
innovative activities. Using the reported author affiliations, we distinguish collaborations 
according to different types of collaboration partners and build measures that account for 
the position of a particular firm within the co-publication network. These measures are 
included in the econometric analysis focusing on firms, their relations and positions within 
the co-publication network.
We use the number of new molecular entities approved by the FDA as a proxy for firms’ 
innovative success with product innovations. Hence, the dependent variable determines 
the use of count data regression models with the Poisson model as the benchmark model 
for the empirical analysis. An important property of the Poisson regression framework 
is equidispersion, i.e. the variance is equal to the mean. We test this assumption using 
a regression-based test as proposed by Cameron and Trivedi (1990) and find significant 
overdispersion in all model specifications. Therefore, we use the negative binomial model 
with Huber–White robust standard errors for our econometric analysis.9
3.3 Variables and descriptive statistics
In our regression analysis, we concentrate on firms, their collaboration partners, network 
positions and new products. Table 1 provides an overview of the variables used in the 
analysis and their descriptive statistics.
We use the number of new molecular entities (NME04–08) as the dependent variable 
(Cerda 2007; Grabowski and Wang 2006). This variable encompasses all new molecular enti-
ties, i.e. active ingredients which have never before been marketed in the US, and that were 
approved by the FDA from 2004 to 2008. During our period of observation 19 NMEs were 
approved in at least one of the 30 medical indications considered by this study. Thirteen of 
these NMEs could be assigned to 10 of the 139 companies included in our firm sample. This 
8http://www.recap.com/, a description of the database can be also found in schilling (2009).
9Because the approval of new pharmaceuticals is rather rare event, the number of observed zeros might be higher than the 
count data models predict. overdispersion might be the consequence of an excess number of zeros in the data. negative 
binomial models take overdispersion and zero observations much better into account than the standard Poisson model. 
Moreover, in general it is not recommended to use zero-inflated models with small sample sizes and zero-inflated models do 
not necessarily lead to considerable improvements with respect to the goodness of fit criteria (Cameron and trivedi 2009). 
the vuong test is usually applied in the literature to test for zero-inflation. the required zero-inflated models did, however, 
not converge in our case.
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number may seem quite low, however, the total number of FDA approved new molecular 
entities has hardly exceeded 20 in recent years and even large pharmaceutical companies 
produce on average a rather low number of NMEs per year (Munos 2009). Pharmaceutical 
cancer research has been described as a field with rather low success rates (Kola and Landis 
2004).
Accordingly, we count NMEs rather than patents. We count a NME as a single innovation 
although it might be used as a treatment for more than one type of cancer in order not to 
overstate the actual number of new products in the therapeutic area of cancer.
Our explanatory variables are constructed using social network analysis. To account for 
the number of collaboration partners, we calculate the number of different organizations 
a firm is linked to in the network during the years 1998–2002 through co-publications 
(Degree98−02). We further distinguish whether collaboration takes place with different part-
ners from academia or different biotechnology companies because particularly these two 
types of organizations may provide access to knowledge relevant for the development of new 
pharmaceuticals (Cockburn and Henderson 1996, 1998; Rothaermel 2001). More precisely, 
we define AcademicPartner98−02 as the number of different academic partners, i.e. universi-
ties, research institutes and university hospitals, from 1998 to 2002. BiotechPartner98−02 rep-
resents the number of different collaboration partners during the period from 1998 to 2002.
Additionally, we account for the total number of different organizations to which firms 
are indirectly linked during the years 1998–2002 (IndirectTies98−02). Specifically, we compute 
the number of organizations to which a firm is linked to at path length 2. Hence, a firm is 
connected to these organizations through its direct collaboration partners. Similarly, we 
calculate the number of indirect ties to academia (IndirectAcademicTies98−02) and biotech-
nology companies (IndirectBiotechTies98−02).
In order to consider companies’ connectivity of its direct collaboration partners, we 
calculate firms’ eigenvector centralities defined as the sum of connections to other actors, 
weighted by their centrality scores (Bonacich 1972, 1987, 2007):
This equation is solved using the eigenvectors and eigenvalues of the adjacency matrix 
(Bonacich 1972, 1987). N refers to the total number of actors. ci, j is a binary indication of 
whether two actors i and j are connected. λ denotes the largest eigenvalue of the adjacency 
matrix. Actors with high eigenvector centrality scores are connected to many other actors 
who are well connected.
Moreover, BetweennessCentrality98−02 accounts for the extent to which an actor can be 
regarded as a gatekeeper or broker in the network. Following Freeman (1977), we can 
express a standardized betweenness centrality index as follows:
Eigenvector Centralityi =
N∑
j=1
ci,jEigenvector Centralityj
휆
Betwenness Centralityi =
2 ∗
∑
j<k
gjk(ai)
gjk
(N − 1)(N − 2)
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with i being distinct from j and k, gjk (ai) denotes the total number of the shortest paths 
linking actors j and k containing actor i. The probability that two actors, j and k, are linked 
by a distinct actor i is provided by gjk (ai)/gjk.
We account for two different strategies to access new knowledge by calculating the extent 
to which firms use one or the other. One strategy is for firms to engage in more informal 
modes of collaboration and encourage their employees to participate in research activities 
with internal and external colleagues. A second strategy is for firms to predominantly use 
more formal modes of collaboration like strategic alliances. More precisely, we divide the 
number of strategic R&D alliances a company is engaged in by the number of collaborations 
in scientific publications (FormalCollab98−02).
LargestComponent98−02 is a dummy equaling 1 if a firm is a member of the largest com-
ponent, i.e. the largest connected part of the network, from 1998 to 2002. The underlying 
assumption for using this variable is that knowledge is exchanged within the connected 
part of the network. Being part of the largest component should then influence the degree 
to which firms can profit from the ongoing knowledge exchange. Moreover, we account 
for firm size (Employees98−02) using the log of the average number of employees from 1998 
to 2002. R&DIntensity98−02 accounts for the average R&D intensity of a firm from 1998 to 
2002. Following the Eurostat definition of R&D intensity10, we calculate this measure using 
firms’ R&D expenses divided by its operating revenues. The operating revenues of firms 
are used instead of sales accounts for the particularities of the industry since many of those 
companies do not generate revenues from selling products. But instead obtain licensing fees 
and (upfront) payments related to their R&D activities. The dummy variable PharmaFirm 
equals one if a firm is active in the development or manufacturing of pharmaceuticals and 
its main activities do not fulfill the biotechnology definition of the OECD (2005). We add 
further dummies indicating whether a company’s headquarter is located either in Asia or 
Oceania (Asia) or in Europe (Europe).11
As shown in Table A2 in the Appendix 1, many of our variables for partners and net-
work positions of firms are rather highly correlated. The main reasons for the considerable 
correlation are that the variables are related through the underlying research network and 
that some variables are more specific subsets of others. Therefore, we introduce each col-
laboration variable separately in the regression models.
4. Regression results
4.1 Partner types and innovative performance
This section reports the findings of our econometric analysis referring to the hypotheses 
developed in the literature review as well as additional tests to be able to better interpret 
our results relative to the theory. Tables 2 and 3 present the results of the negative binomial 
regressions using the number of new molecular entities approved between 2004 and 2008 
(NME04–08) in the field of cancer as dependent variable. In contrast to Tables 2, Table 3 con-
trols for the ratio of R&D alliances and collaborations in publications (FormalCollab98−02).
In support of Hypothesis 1, we find a robust positive relationship between firms’ total 
number of different collaboration partners (Degree98−02) and their innovative performance. 
10http://ec.europa.eu/eurostat/statistics-explained/index.php/Glossary:r_%26_d_intensity.
11there are no companies headquartered in africa or Latin america in our data-set.
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This result suggests that joint knowledge generation is needed with a diverse set of partner 
organizations. These collaborations provide access to knowledge, expertise, research mate-
rials and other resources to support the successful development of new pharmaceuticals.
Hypothesis 2 was presented as both a positive and negative hypothesis, due to mixed 
results in previous research about whether or not having biotechnology partners is positively 
associated with the innovative performance. Neither H2a nor H2b could be supported. 
While other research emphasizes the importance of biotechnology for drug discovery and 
provision of research techniques, our results suggest that, at least for cancer, having a bio-
technology partner is neither positively nor negatively linked to product innovation.
Hypothesis 3 suggests the benefits of collaborations with academic institutions 
(AcademicPartners98−02), and is supported in Model (3) in Table 2. Companies’ innova-
tive activities benefit from these collaborations, and our interpretation is that academic 
institutions provide access to relevant basic and clinical bio-medical knowledge that is not 
available to the firm in-house. Moreover, companies can increase their absorptive capacity 
through the joint generation and application of knowledge as indicated in co-publication 
projects with academic collaborators. They likely also benefit from their partners’ scien-
tific reputation. Nevertheless, we do not find evidence for a positive relationship between 
co-publication links to academic institutions and companies’ innovative performance if we 
control for FormalCollab98−02 in Model (3) in Table 3. Our interpretation is that companies 
with numerous R&D alliances have sufficient opportunities to access external knowledge 
which reduces the importance of joint knowledge generation with partners from academia.
Moreover, our results provide support for hypotheses 4, 5a and 6, thereby indicating the 
importance of indirect connections within the co-publication network. In particular, firms 
may benefit from indirect connections in general (IndirectTies98−02), indirect connections to 
biotechnology companies (IndirectBiotechTies98−02), and indirect connections to academia 
(IndirectAcademicTies98−02). Hence, indirect connections are important ways for companies 
to access knowledge of their partners’ partners, and especially biotechnology companies 
and academic institutions. Our interpretation is that the firms can use indirect connections 
to access knowledge, which in turn can be incorporated into a firm’s internal knowledge 
base in order to promote product innovation.
However, with respect to firms’ network positions, we find neither evidence that firms 
can benefit from a high number of collaborations if their partners are highly connected 
(EigenvectorCentrality98−02) as proposed in Hypothesis 7 nor do they benefit from a gate-
keeper position within the network (BetweennessCentrality98−02) as suggested in Hypothesis 
8. This result is more puzzling, as it contradicts previous research in general and for this 
industry, as discussed in the final section.
Finally, a discussion of control variables follows. We find no significant relationship 
between the number of NMEs as a proxy for product innovation and the extent to which 
firms engage in scientific collaborations as opposed to strategic alliances (FormalCollab98−02). 
Membership in the largest component of the network (LargestComponent98−02) is positively 
and significantly related to product innovation, thereby supporting the argument that firms 
must be linked to the largest connected part of the network to benefit from the knowledge 
flows within it.
While larger firms (Employees98−02) generate a higher number of product innovations in 
the field of cancer, we do not find a robust (positive) relationship between firms’ R&D inten-
sity (R&DIntensity98−02) and product innovation. On the one hand, this finding might be 
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driven by the measure for R&D intensity, which captures companies overall R&D expenses, 
instead of only those related to cancer. On the other hand, this result may suggest a need for 
a deeper understanding of underlying processes. It is also possible that in this science-based 
and R&D intense industry, R&D expenditures may not fully account for more informal 
modes of knowledge generation that we analyze with the variables for different types of 
collaboration partners.
We do find a positive and significant relation between PharmaFirm and the number of 
new molecular entities. This result suggests that product innovations in the field of cancer 
are dominated by pharmaceutical companies which have the required expertise in clinical 
research and drug approval. Firms headquartered in Asia show a higher number of product 
innovations in the field of cancer than their counterparts headquartered in North America; 
whereas, we find no robust relationship for companies headquartered in Europe.
4.2 Robustness checks
Empirical analyses of co-publication and other knowledge networks face the challenge of 
endogeneity due to omitted variables and reverse causality (Phelps, Heidl, and Wadhwa 
2012). We address this issue in different ways.
Firstly, we use the total number of NMEs, i.e. the sum of NMEs in cancer and the number 
of NMEs in other disease areas, for the years from 1998 to 2002 as an additional control 
variable to mitigate the problem of omitted variables. The results suggest a rather robust 
positive relationship between the number of total lagged NMEs and the number of NMEs 
in the disease area of cancer. In accordance with our original findings, these results indicate 
a positive relationship between the number of indirect partners (IndirectTies98–02) as well as 
the number of indirect academic partners (AcademicPartners98–02) and the number of NMEs 
in cancer. In contrast to our original results, the coefficients for Degree98–02 and the number 
of indirect biotechnology partners (IndirectBiotechTies98–02) are not significantly related to 
successful new product development. These results are robust to the inclusion of the ratio 
of R&D alliances and publication collaborations (FormalCollab98−02). Consequently, we find 
additional support for the importance of indirect partners in general, and especially for 
academic partners (but not for biotechnology partners) for the successful development of 
product innovations in terms of new cancer drugs.
Secondly, we investigate whether companies’ innovative success affects their collabo-
ration activities rather than vice versa. Building upon earlier work (e.g. Criscuolo, Salter, 
and Ter Wal 2014) based on the ideas of Granger (1969) we test whether the number of 
lagged NMEs (NME98–02) in the disease area of cancer is significantly related to the number 
of companies’ collaboration partners or their centrality scores. Controlling for the number 
of lagged collaboration partners and lagged centrality scores, the results do not suggest 
the presences of reverse causality with respect to the number of the different collaboration 
partners. However, we find a positive and significant relation between NME98–02 and the 
centrality scores. Consequently, we cannot rule out reverse causality for eigenvector and 
betweenness centrality. Since both measures are not significant in our original regressions, 
this finding does not invalidate the conclusion from our original analysis.
Our results, particularly for indirect partners, stay qualitatively the same if we restrict our 
results to firms that are part of the network’s main component, to articles that are published 
in journals included in the WoS prior to 1998, and to journal articles published in journals 
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classified as “basic research” according to the CHI classification of journals (Hamilton 
2003). With the exception of the number of biotechnology companies a firm is indirectly 
connected to, we find no evidence of an inverted u-shaped relationship between the number 
of direct or indirect collaboration partners and product innovation.
In addition, we conducted negative binomial regressions using the share of direct and 
indirect academic and biotechnology partners for the period 1998–2002 instead of their 
count as independent variables. The corresponding results are rather similar to the results 
of the original analysis. More precisely, we find a robust positive and significant relationship 
between the share of indirect biotechnology partners and the number of NMEs. In con-
trast to our original analysis which indicated a positive relationship between the number 
of indirect academic partners and the number of NMEs, we do not find a significant rela-
tionship between the share of indirect academic partners and the number of NMEs. One 
explanation for this finding can be that companies that have very few collaboration partners 
in the co-publication network may predominantly rely on collaborations with academic 
institution. Consequently, the relative importance of collaborators form academia is quite 
high despite the limited total number of academic partners and the limited potential to 
benefit from knowledge flows in the network.
5. Conclusions
In contrast to other industries, the biotechnology and pharmaceutical industry is highly 
dependent upon public science as well as collaboration with diverse partners in order to 
advance medical and technical understanding as well as to discover and test new pharma-
ceuticals. Therefore, the main reasons why companies in this industry must collaborate with 
different types of partners include the further development of companies’ own knowledge 
base as well as the access to complementary knowledge in an environment of rapid scien-
tific advances. Within this empirical context, this paper has focused upon untangling the 
influence of the firm’s collaborative relations with different partner types and their network 
position on successful product innovation. In doing so, we focus on the development of 
new pharmaceuticals in the disease area of cancer. This disease area is an interesting area to 
study due to the spread of the disease, the large public investments into scientific research 
and the high degree of novelty in the product innovations required for treatment and 
diagnosis of the disease.
Our results suggest that direct and indirect co-publication links to diverse partners are 
beneficial for successful product innovation, as would be expected from existing litera-
ture. However, direct co-publication links with academic institutions and biotechnology 
companies do not unambiguously contribute to companies’ innovative performance while 
indirect linkages do.
In accordance with Ahuja (2000), we find that direct and indirect linkages to diverse 
partners are beneficial for pharmaceutical product innovation in the disease area of cancer. 
This result suggests that companies should invest in establishing and maintaining linkages 
to a divers set of partners. In the more detailed analysis, our results indicate that not only 
direct collaboration with academic partners is beneficial for the successful development 
of new drugs. Moreover, companies seem to benefit from knowledge flows from academic 
institutions with which they are only indirectly connected. Firms need a wide range of direct 
and indirect linkages to academic institutions because such connections provide knowledge 
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and expertise necessary to explore and to exploit scientific and technological opportunities, 
in a rapidly moving and expanding field.
Research suggests that collaboration, e.g. through strategic alliances, with biotechnology 
companies is an important translation mechanism of knowledge generated in  academia into 
marketable products (Rothaermel 2001). In contrast, our results suggest that co- publication 
with biotechnology companies is a rather rare event. Moreover, we do not find a signifi-
cant association with firms’ innovative performance. One explanation for our finding is, 
as argued in existing literature, that biotechnology companies primarily serve as  suppliers 
of research methods and promising compounds for new pharmaceuticals along the indus-
try’s knowledge supply chain (Nightingale and Mahdi 2006). As suppliers of methods 
and compounds they are only to a minor extent involved into collaborative research with 
pharmaceutical companies that leads to co-publications. An alternative explanation, which 
seems quite plausible, is that large pharmaceutical companies have developed biotechnology 
capabilities in-house, which implies that for this type of knowledge, they can develop ideas 
in-house or directly with academic institutions and therefore do not need to collaborate 
with  biotechnology firms.
Moreover, we neither find evidence that firms can benefit from a gatekeeper nor a 
knowledge broker position within the network. They also do not benefit from a high con-
nectedness of their collaboration partners. Our results thus contradict previous research 
suggesting a  positive relation between eigenvector centrality and innovative performance 
(Powell et al. 1999) as well as between betweenness centrality and firms’ innovative 
 performance ( Owen-Smith and Powell 2004). Our interpretation, which requires  additional 
research to validate, is that the value of the network position per se for innovation has 
been  overemphasized in  previous research. At the same time, the importance of inter-
nal  capabilities of the firm as well as the type of partners have been underemphasized. 
While companies need capabilities to effectively and efficiently use the knowledge they 
are  confronted with in central network positions, the usefulness of this knowledge may 
depend on the diversity of connections within the network (Kogut and Zander 1992; Ter 
Wal et al. 2013).
Taken together, our interpretation of these results is that companies’ main benefits in the 
co-publication network may not originate from joint knowledge generation through direct 
collaboration with organizations of different types. Instead, companies’ drug development 
activities primarily benefit from knowledge that originates from direct partners’ collabo-
ration partners. With respect to economic theory, this interpretation suggests a need for 
reconsidering the ways of how knowledge is generated and transferred in co- publication 
projects and their importance for product innovation, particularly in  science-based 
 industries. Moreover, these results suggest refining our understanding of the circumstances 
under which direct or indirect connections via co-publications network are beneficial for 
product innovations.
An interesting issue for further research is whether and how networks help to mitigate 
the problem of declining productivity in R&D in the pharmaceutical industry. Our results 
strongly suggest that biotechnology companies are not core partners for the large pharma-
ceutical firms—at least not in cancer and not when one links co-publication networks to 
product innovations. Therefore, future research on the relationship between biotechnology 
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firms and large pharmaceutical firms should focus on whether partnering with biotech-
nology firms does in fact provide knowledge and techniques that help to stimulate in an 
indirect manner product innovations in large pharmaceutical companies.
Also, given that our results differ in important ways from previous research, our recom-
mendation is that later research follows dimensions of our research design, which differs 
from much of previous research, in order to examine whether our results are robust across 
different industries or disease areas in pharmaceuticals. More precisely, we recommend three 
improvements to research design: (1) Examine co-publications of scientific articles, rather 
than the commonly used databases of collaborative agreements in general, if the foci are 
on the generation and development of knowledge. (2) Employ a better proxy for product 
innovation such as NME rather than the commonly used one of patents. In comparison 
with NMEs, patents do not fully capture the idea of product innovation in a specific dis-
ease area. This is because, in this industry patent applications are usually filed shortly after 
the discovery of a new compound. At this time its therapeutic potential as well as its use 
against a particular indication is not yet fully examined and its successful market approval 
cannot be foreseen.12 (3) Limit an analysis to a specific disease area, rather than examining 
the whole industry, because this gives a more precise measurement and understanding of 
particular knowledge and innovation processes.
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Appendix 1
Table A1. list of Medical Indications
angiogenesis Liver Cancer
Bladder Cancer Lung Cancer
Bone Cancer Lymphoma
Brain Cancer Melanoma
Breast Cancer Metastasis
Cervical Cancer Mouth or throat Cancer
Chemotherapy related Mucositis
Colon Cancer Multiple myeloma
Endometrial Cancer non-Hodgkin Lymphoma
Gastrointestinal Cancer ovarian Cancer
Head and neck Cancer Pancreatic Cancer
Hematological Cancer Prostate Cancer
Kaposi sarcoma radiation related
Kidney Cancer soft-tissue sarcoma
Leukemia solid tumors
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Table A2. correlations
  (1) (2) (3) (4) (5) (6)
(1) degree98–02 1.0000
(2) academicPartners98–02 0.9435*** 1.0000
(3) BiotechPartners98–02 0.5405*** 0.3630*** 1.0000
(4) Indirectties98–02 0.8423*** 0.8446*** 0.4190*** 1.0000
(5) Indirectacademicties98–02 0.8179*** 0.8105*** 0.4229*** 0.9965*** 1.0000
(6) IndirectBiotechties98–02 0.7730*** 0.8285*** 0.2723** 0.9135*** 0.8990*** 1.0000
(7) BetweennessCentrality98–02 0.5865*** 0.5780*** 0.2760** 0.6315*** 0.6263*** 0.6628***
(8) EigenvectorCentrality98–02 0.7948*** 0.8188*** 0.2951*** 0.6755*** 0.6488*** 0.6488***
(9) FormalCollab98−02 −0.1405 −0.1290 −0.1085 −0.1413 −0.1432 −0.0941
(10) LargestComponent98–02 0.0617 0.0555 0.0450 0.0000 0.0000 0.0000
(11) Employees98–02 0.4432*** 0.4164*** 0.3336*** 0.4029*** 0.3953*** 0.3368***
(12) r&dIntensity98–02 −0.1454 −0.1229 −0.1101 −0.1228 −0.1259 −0.0795
(13) PharmaFirm 0.3565*** 0.3719*** 0.1800* 0.3405*** 0.3334*** 0.2618**
(14) asia −0.1363 −0.0874 −0.1044 −0.0980 −0.1163 −0.1512
(15) Europe 0.2850*** 0.2932*** 0.1612 0.1840* 0.1741* 0.1551
  (7) (8) (9) (10) (11) (12)
(7) BetweennessCentrality98–02 1.0000
(8) EigenvectorCentrality98–02 0.2396** 1.0000
(9) FormalCollab98−02 −0.0779 −0.0873 1.0000
(10) LargestComponent98–02 0.0393 0.0361 −0.3251*** 1.0000
(11) Employees98–02 0.2582** 0.3165*** −0.2588** 0.0116 1.0000
(12) r&dIntensity98–02 −0.0934 −0.0961 0.2426** 0.0319 −0.4316*** 1.0000
(13) PharmaFirm 0.2677** 0.1903* −0.1596 −0.0373 0.2345** −0.0252
(14) asia −0.1392 −0.1297 −0.1009 −0.0934 0.2797*** −0.1788*
(15) Europe 0.2338** 0.1600 −0.1396 0.0607 0.2051* −0.1392
(13) (14) (15)
(13) PharmaFirm 1.0000
(14) asia 0.0564 1.0000
(15) Europe 0.1550 −0.2466** 1.0000
*p < 0.05, **p < 0.01, ***p < 0.001.
